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Introduction
The nuclear oncoprotein DEK is a biochemically distinct,
pro-inflammatory protein that is a chemoattractant for
neutrophils and T-cells. High levels of DEK autoantibo-
dies have been found in several autoimmune diseases
including juvenile idiopathic arthritis (JIA), but their role
in disease pathogenesis is unclear.
Objectives
Since DEK and DEK autoantibodies can contribute to the
development of immune complexes and joint inflamma-
tion, we suggest that DEK antibody levels can predict dis-
ease flare with discontinuation of anti-TNF therapy.
Methods
In 16 pediatric rheumatology centers, sera samples were
collected from 137 children with polyarticular JIA on
anti-TNF therapy. Therapy was stopped after 6 months
for patients with clinically inactive disease (CID). Disease
activity was then monitored for 14 months or until dis-
ease flare. DEK antibody levels were measured by ELISA
in sera collected at time of enrollment, disease flare off
therapy, or end of study. DEK antibody levels relative to
healthy controls were calculated by area under the curve
(AUC), expressed as unit-free ratios.
Results
103 female and 34 male patients with polyarticular JIA
were enrolled, mean age 11.3 years and disease duration
of 5.0 years (77% were on etanercept, 18% adalimumab,
5% infliximab, and 40% concurrent methotrexate).
31 patients discontinued the study for various reasons,
including loss of CID during therapy. 39 patients flared
within 14 months of stopping therapy, but 67 subjects
had no flare within those 14 months. In 89 patients’ sam-
ples collected at the end of the study or at time of flare,
DEK antibody levels compared to healthy controls ranged
from -0.69 (some patients had lower antibody levels than
did healthy controls) to 0.83, mean difference of 0.068
(Q1-Q3 of -0.25-0.28 and 0.025 (SD, 0.39). High levels of
DEK antibodies, mean and SD of 0.164 ± 0.39, with 95%
confidence interval of (0.02, 0.31), were detected in 30 of
the patients that flared within 14 months as compared to
lower levels of DEK antibodies (-0.05 ± 0.39, 95% confi-
dence interval of (-0.15, 0.05)) measured in 59 of the
patients with no disease flare for 14 months (Student-T,
P=0.016). Thus, patients that experience flare within
14 months of stopping anti-TNF therapy have signifi-
cantly increased levels of DEK antibodies compared to
patients that maintained their CID till the end of the
study.
Conclusion
In children with polyarticular JIA on anti-TNF therapy
that maintain CID for at least 6 months while on therapy,
high DEK antibody levels may correlate with flare within
the first 14 months after stopping therapy. This study
suggests that DEK antibody levels might predict the out-
come of discontinuation of anti-TNF therapy.
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